Abstract
<div>Abstract<p>Worldwide oral squamous cell carcinoma (OSCC) represents about 5.5% of all malignancies, with ∼30,000 new cases each year in the United States. The integrin α<sub>v</sub>β<sub>6</sub> and the enzyme cyclooxygenase-2 (COX-2) are implicated in OSCC progression and have been suggested as possible therapeutic targets. Each protein also is reported to identify dysplasias at high risk of malignant transformation, and current clinical trials are testing the efficacy of nonsteroidal anti-inflammatory drugs (NSAID) at preventing OSCC development. Given the probable increased expression of α<sub>v</sub>β<sub>6</sub> and COX-2 in OSCC and the inhibition of several integrins by NSAIDs, we investigated whether NSAIDs affected α<sub>v</sub>β<sub>6</sub>-dependent cell functions. We found that expression of both α<sub>v</sub>β<sub>6</sub> and COX-2 was significantly higher in OSCC compared with oral epithelial dysplasias. Neither protein preferentially identified those dysplastic lesions that became malignant. Using OSCC cell lines, modified to express varying levels of α<sub>v</sub>β<sub>6</sub>, we assessed the effect of COX-2 inhibition on cell invasion. We found that the COX-2 inhibitor NS398 inhibited specifically α<sub>v</sub>β<sub>6</sub>-dependent, but not α<sub>v</sub>β<sub>6</sub>-independent, OSCC invasion <i>in vitro</i> and <i>in vivo</i>, and this effect was modulated through prostaglandin E<sub>2</sub> (PGE<sub>2</sub>)–dependent activation of Rac-1. Transient expression of constitutively active Rac-1, or addition of the COX-2 metabolite PGE<sub>2</sub>, prevented the anti-invasive effect of NS398. Conversely, RNA interference down-regulation of Rac-1 inhibited α<sub>v</sub>β<sub>6</sub>-dependent invasion. These findings suggest that COX-2 and α<sub>v</sub>β<sub>6</sub> interact in promoting OSCC invasion. This is a novel mechanism that, given the ubiquity of α<sub>v</sub>β<sub>6</sub> expression by head and neck cancers, raises the possibility that NSAIDs could protect against OSCC invasion. (Cancer Res 2006; 66(22): 10833-42)</p></div>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.